Cargando…

CD248: A therapeutic target in cancer and fibrotic diseases

CD248/endosialin/TEM1 is a type 1 transmembrane glycoprotein found on the plasma membrane of activated mesenchymal cells. CD248 functions during embryo development and is either not expressed or found at very low levels in adult tissues. CD248 is expressed at high levels by malignant sarcoma cells,...

Descripción completa

Detalles Bibliográficos
Autor principal:	Teicher, Beverly A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398180/ https://www.ncbi.nlm.nih.gov/pubmed/30847027 http://dx.doi.org/10.18632/oncotarget.26590

Ejemplares similares

CD248 as a novel therapeutic target in pulmonary arterial hypertension
por: Xu, Tao, et al.
Publicado: (2020)

Retracted: CD248 as a novel therapeutic target in pulmonary arterial hypertension
Publicado: (2021)

Cd248a and Cd248b in zebrafish participate in innate immune responses
por: Li, Xianpeng, et al.
Publicado: (2022)

CD248(+) Cancer-Associated Fibroblasts: A Novel Prognostic and Therapeutic Target for Renal Cell Carcinoma
por: Xu, Chao, et al.
Publicado: (2021)

Endosialin/CD248 may be a potential therapeutic target to prevent the invasion and metastasis in osteosarcoma
por: Kondo, Yumiko, et al.
Publicado: (2022)

Therapeutic potential for targeting Annexin A1 in fibrotic diseases
por: Yan, Zhibin, et al.
Publicado: (2022)

CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma
por: Liu, Shaojie, et al.
Publicado: (2021)

Targeting cullin neddylation for cancer and fibrotic diseases
por: He, Zhang-Xu, et al.
Publicado: (2023)

Targeting fibroblast CD248 attenuates CCL17-expressing macrophages and tissue fibrosis
por: Pai, Chen-Hsueh, et al.
Publicado: (2020)

The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
por: Zhang, Keying, et al.
Publicado: (2021)

Microvascular Targets for Anti-Fibrotic Therapeutics
por: Pu, Kai-Ming T., et al.
Publicado: (2013)

Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease
por: Sampson, Natalie, et al.
Publicado: (2012)

Gasotransmitters: Potential Therapeutic Molecules of Fibrotic Diseases
por: Chen, Yingqing, et al.
Publicado: (2021)

CD248 facilitates tumor growth via its cytoplasmic domain
por: Maia, Margarida, et al.
Publicado: (2011)

Interference in melanoma CD248 function reduces vascular mimicry and metastasis
por: Kuo, Cheng-Hsiang, et al.
Publicado: (2022)

Sex-specific effects of CD248 on metabolism and the adipose tissue lipidome
por: Patrick, Kieran, et al.
Publicado: (2023)

Redox Signaling as a Therapeutic Target to Inhibit Myofibroblast Activation in Degenerative Fibrotic Disease
por: Sampson, Natalie, et al.
Publicado: (2014)

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts
por: Liu, Shaojie, et al.
Publicado: (2022)

Hydrogen Sulfide: A Therapeutic Candidate for Fibrotic Disease?
por: Song, Kai, et al.
Publicado: (2015)

Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis
por: Bartis, Domokos, et al.
Publicado: (2016)

Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
por: Li, Yu, et al.
Publicado: (2021)

The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target
por: Enzo, Maria Vittoria, et al.
Publicado: (2015)

Abstract 99: Isolation of CD248 Expressing Adipose Derived Stromal Cells for Targeted Improvement of Wound Healing
por: Brett, Elizabeth, et al.
Publicado: (2017)

A Differential Role for CD248 (Endosialin) in PDGF-Mediated Skeletal Muscle Angiogenesis
por: Naylor, Amy J., et al.
Publicado: (2014)

Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics
por: Dolivo, David, et al.
Publicado: (2021)

Health Tract, No. 248: Weights and Measures
Publicado: (1866)

CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes
por: Matsushima, Sayomi, et al.
Publicado: (2020)

Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases
por: Zhu, Junyan, et al.
Publicado: (2023)

Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target
por: Marangoni, Roberta G., et al.
Publicado: (2017)

Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature
por: Rybinski, Katherine, et al.
Publicado: (2015)

Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer
por: Li, Chunsheng, et al.
Publicado: (2014)

Therapeutic Approach to Adult Fibrotic Lung Diseases
por: Adegunsoye, Ayodeji, et al.
Publicado: (2016)

Therapeutic Targeting of Fibrotic Epithelial-Mesenchymal Transition–An Outstanding Challenge
por: Fintha, Attila, et al.
Publicado: (2019)

Role of Ferroptosis in Fibrotic Diseases
por: Zhou, Jian, et al.
Publicado: (2022)

P248 Fungal meningitis in an immunocompetent individual
por: Ningthoujam, Priyolakshmi, et al.
Publicado: (2022)

Immuno-imaging and -therapy in ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targeting TEM1/CD248
por: Li, Chunsheng, et al.
Publicado: (2014)

The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders
por: Di Gregorio, Jacopo, et al.
Publicado: (2020)

G Protein-Coupled Receptor Kinase 2 as Novel Therapeutic Target in Fibrotic Diseases
por: Li, Nan, et al.
Publicado: (2022)

Potential therapeutic targets of macrophages in inhibiting immune damage and fibrotic processes in musculoskeletal diseases
por: Zhu, Jianshu, et al.
Publicado: (2023)

SAT-248 Cushing’s Disease with Two ACTH-Producing Pituitary Tumors
por: Mathai, Christine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4ee5t72auc1f378reafb9c7v9